MX2009012628A - Compuestos de triazol para tratar formacion de biopelicula. - Google Patents

Compuestos de triazol para tratar formacion de biopelicula.

Info

Publication number
MX2009012628A
MX2009012628A MX2009012628A MX2009012628A MX2009012628A MX 2009012628 A MX2009012628 A MX 2009012628A MX 2009012628 A MX2009012628 A MX 2009012628A MX 2009012628 A MX2009012628 A MX 2009012628A MX 2009012628 A MX2009012628 A MX 2009012628A
Authority
MX
Mexico
Prior art keywords
biofilm formation
triazol
treating biofilm
triazol compounds
compounds
Prior art date
Application number
MX2009012628A
Other languages
English (en)
Spanish (es)
Inventor
David Reid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38534753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009012628(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009012628A publication Critical patent/MX2009012628A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009012628A 2007-05-22 2008-05-21 Compuestos de triazol para tratar formacion de biopelicula. MX2009012628A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07108650A EP1994930A1 (en) 2007-05-22 2007-05-22 Triazol compounds for treating biofilm formation
PCT/EP2008/056231 WO2008142094A1 (en) 2007-05-22 2008-05-21 Triazol compounds for treating biofilm formation

Publications (1)

Publication Number Publication Date
MX2009012628A true MX2009012628A (es) 2009-12-07

Family

ID=38534753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012628A MX2009012628A (es) 2007-05-22 2008-05-21 Compuestos de triazol para tratar formacion de biopelicula.

Country Status (18)

Country Link
US (2) US8309590B2 (enExample)
EP (3) EP1994930A1 (enExample)
JP (1) JP5470245B2 (enExample)
KR (1) KR101519675B1 (enExample)
CN (2) CN103381271A (enExample)
AU (1) AU2008252964B2 (enExample)
BR (1) BRPI0811103A2 (enExample)
CA (1) CA2685112A1 (enExample)
CL (1) CL2008001469A1 (enExample)
IL (1) IL201832A (enExample)
MA (1) MA31388B1 (enExample)
MX (1) MX2009012628A (enExample)
NZ (1) NZ580735A (enExample)
RU (1) RU2478385C2 (enExample)
TN (1) TN2009000487A1 (enExample)
TW (1) TWI419690B (enExample)
WO (1) WO2008142094A1 (enExample)
ZA (1) ZA200907415B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
RU2646488C2 (ru) * 2016-04-25 2018-03-05 Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОрГМУ Минздрава России) Средство для селективного влияния на биопленкообразование микроорганизмами
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN110448693A (zh) * 2019-07-30 2019-11-15 华东理工大学 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004438A (en) * 1991-12-31 1999-12-21 3M Innovative Properties Company Biofilm reduction sterilizer
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
WO1997049397A1 (en) * 1996-06-26 1997-12-31 Sankyo Company, Limited Novel medicinal compositions of hydropyridines
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
WO2001070213A2 (en) 2000-03-23 2001-09-27 Influx, Inc. Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure
WO2002076439A2 (en) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
GB0205593D0 (en) * 2002-03-09 2002-04-24 Univ Nottingham Treatment of surfaces populated by bacteria
US20040043052A1 (en) * 2002-05-24 2004-03-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for coating medical implants
US7498292B2 (en) 2002-08-15 2009-03-03 The Research Foundation Of State University Of New York Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation

Also Published As

Publication number Publication date
TN2009000487A1 (en) 2011-03-31
RU2009147297A (ru) 2011-06-27
JP5470245B2 (ja) 2014-04-16
US20100152101A1 (en) 2010-06-17
EP2253317A2 (en) 2010-11-24
AU2008252964A1 (en) 2008-11-27
KR101519675B1 (ko) 2015-05-12
BRPI0811103A2 (pt) 2014-12-09
NZ580735A (en) 2012-02-24
US8309590B2 (en) 2012-11-13
KR20100017153A (ko) 2010-02-16
JP2010527960A (ja) 2010-08-19
CN101678004A (zh) 2010-03-24
ZA200907415B (en) 2010-07-28
US8592473B2 (en) 2013-11-26
MA31388B1 (fr) 2010-05-03
EP1994930A1 (en) 2008-11-26
IL201832A0 (en) 2010-06-16
RU2478385C2 (ru) 2013-04-10
AU2008252964B2 (en) 2011-12-01
CL2008001469A1 (es) 2010-10-29
IL201832A (en) 2015-11-30
WO2008142094A1 (en) 2008-11-27
TWI419690B (zh) 2013-12-21
TW200913996A (en) 2009-04-01
EP2162130A1 (en) 2010-03-17
EP2253317A3 (en) 2011-03-16
CN103381271A (zh) 2013-11-06
WO2008142094A4 (en) 2009-01-29
CA2685112A1 (en) 2008-11-27
US20120329746A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
TN2009000487A1 (en) Triazol compounds for treating biofilm formation
WO2003063864A3 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
ZA201002596B (en) 1,2,3-triazole derivatives for use as stearoyl-coa destaurase inhibitors
WO2007066189A3 (en) Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2010032147A3 (en) Hydroxamic acid derivatives useful as antibacterial agents
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
JP2010515715A5 (enExample)
WO2005044192A3 (en) Triazole compounds and uses related thereto
WO2010045251A3 (en) Spiro-oxindole compounds and their use as therapeutic agents
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
NO20082496L (no) Pyrazinderivater
WO2009120660A3 (en) Substituted pyridoxazines
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
GB0710121D0 (en) Antifungal agents
TW200603841A (en) Dispersible tablets comprising a benzoic acid derivative
NO20084913L (no) Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav
MX2009005619A (es) Formas poliformicas del deferasirox (icl670a).
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2006051314A3 (en) Guanidine derivatives as inhibitors of ddah
NO20090193L (no) Substituerte heterocykliske etere og anvendelse derav i CNS forstyrrelser
WO2005065315A3 (en) Bone targeting compounds for delivering agents to the bone for interaction therewith
ZA200707486B (en) Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease
ZA200807800B (en) Use of N-(dibenz (B,F) oxepin-10-ylmethyl) N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration